Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Gibson

Cardiovascular Disease Orange, CA Medical Doctor

NPI 1881920882 CMS profile 1386238

101 The City Dr S, Orange, CA 92868

Open in the dashboard

General payments

$7,790

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,281 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Michael Gibson of Orange, CA is reported in the CMS Open Payments database as having received $7,790 across 83 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,281 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,330 23
2024 General $1,068 16
2023 General $1,695 18
2022 General $2,778 14
2021 General $518 6
2019 General $403 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Gibson
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Michael Gibson were reported at $1,330. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Michael Gibson Cardiovascular Disease median Middle half National median
2019 $403 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $518 $335 $101–$1,037 $132
2022 $2,778 $395 $121–$1,211 $149
2023 $1,695 $443 $136–$1,283 $160
2024 $1,068 $450 $136–$1,323 $164
2025 $1,330 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,438 23 payments
  2. Abiomed $1,850 26 payments
  3. Regeneron Pharmaceuticals, Inc. $710 3 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $442 9 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $421 4 payments
  6. CVRx, Inc. $183 2 payments
  7. LeMaitre Vascular, Inc. $114 1 payment
  8. Novo Nordisk Inc $104 1 payment
  9. Actelion Pharmaceuticals US, Inc. $82 1 payment
  10. Medtronic Vascular, Inc. $74 1 payment
  11. Other $371 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,086 76 payments
  2. Consulting Fee $1,913 3 payments
  3. Travel and Lodging $710 3 payments
  4. Education $82 1 payment
Products named General payments · program years 2019–2025
  1. CARDIOMEMS Heart failure $2,257 7 payments
  2. Impella $1,379 18 payments
  3. LIBTAYO $710 3 payments
  4. CARDIOMEMS Structural Heart $590 8 payments
  5. LifeVest $442 9 payments
  6. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $312 2 payments
  7. Barostim Neo System $183 2 payments
  8. CardioMEMS HF System $150 1 payment
  9. JARDIANCE $124 1 payment
  10. ARTEGRAFT VASCULAR GRAFT $114 1 payment
  11. Other $955 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,448

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$2,501,884

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

38.4%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 37 $1,327,271
Jardiance Empagliflozin Brand 300 $407,703
Entresto Sacubitril/Valsartan Brand 300 $361,964
Eliquis Apixaban Brand 125 $165,848
Farxiga Dapagliflozin Propanediol Brand 52 $64,041
Ozempic Semaglutide Brand 63 $61,883
Ambrisentan Generic 18 $35,627
Xarelto Rivaroxaban Brand 13 $20,246
Verquvo Vericiguat Brand 13 $18,382
Repatha Sureclick Evolocumab Brand 15 $9,066

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$112,945

Medicare's payments for the services billed

Medicare patients

269

Average age 72

Services billed

1,139

116 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Chronic kidney disease 71%
Ischemic heart disease 65%
Atrial fibrillation 61%
Diabetes 57%
Arthritis 46%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $104
$104 300 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $30
$30 — —
TYVASO
  • United Therapeutics Corporation $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record